SCHEMBL5250458

SCHEMBL5250458

CCOC(=O)c1cccc(F)c1CBr

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.56
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 3/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
PLK1 P53350 1/20 0.46
CDC25B P30305 2/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305617 0.87 TSHR (0.59) TSHRALDH1A1HSD17B10KDM4EGLA
SCHEMBL6354255 0.84 TSHR (0.59) TSHRALDH1A1HSD17B10GAAKMT2A
SCHEMBL5557509 0.84 LMNA (0.44) TSHRALDH1A1HSD17B10KDM4EGLA
SCHEMBL30772831 0.83 TSHR (0.58) TSHRALDH1A1HSD17B10KDM4EKMT2A
SCHEMBL8724253 0.83 TSHR (0.58) TSHRALDH1A1HSD17B10KDM4EKMT2A
SCHEMBL22261525 0.81 TSHR (0.47) TSHRALDH1A1HSD17B10KDM4EHPGD
SCHEMBL2601357 0.81 CYP4F2 (0.56) TSHRALDH1A1HSD17B10KDM4EL3MBTL1
SCHEMBL9541307 0.81 TSHR (0.56) TSHRALDH1A1HSD17B10KDM4EKMT2A
SCHEMBL19260569 0.81 TSHR (0.59) TSHRALDH1A1HSD17B10KDM4EGLA
SCHEMBL1656132 0.80 TSHR (0.47) TSHRALDH1A1HSD17B10KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US disclosed
CN-114981265-B Compounds of formula (I) CTXT私人有限公司 2025-01-03 CN disclosed
WO-2023029943-A1 AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 星药科技(北京)有限公司 2023-03-09 WO disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
EP-4077318-A1 COMPOUNDS CTXT PTY LTD (AU) 2022-10-26 EP disclosed
CN-114981265-A Compound (I) CTXT私人有限公司 2022-08-30 CN disclosed
CN-111057074-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2022-04-29 CN disclosed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO disclosed
CN-111057074-A Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-04-24 CN disclosed
EP-1260512-B1 NOVEL CYCLIC AMIDE DERIVATIVES MITSUBISHI PHARMA CORP (JP) 2007-07-04 EP disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 EP disclosed
WO-1993014086-A1 SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1993-07-22 WO disclosed
US-4889858-A ANTIHYPOXIC AGENTS, ANTICONVULSANTS, LIPID PEROXIDATION INHIBITORS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1989-12-26 US disclosed
EP-0269755-A1 DIBENZ b,e OXEPIN DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME AS ACTIVE INGREDIENT Dainippon Pharmaceutical Co., Ltd. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS TSHR 4301/4885ALDH1A1 4610/4885HSD17B10 4392/4885
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 TSHR 332/4885ALDH1A1 690/4885HSD17B10 907/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS TSHR 1389/4885ALDH1A1 4143/4885HSD17B10 3588/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS TSHR 4454/4885ALDH1A1 4079/4885HSD17B10 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.